- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04831827
Promoting Equity for Cancer Screening and Follow-up
Promoting Equity Through Multicomponent Strategies for Cancer Screening and Follow-up (PREMiS)
연구 개요
상태
상세 설명
Colorectal cancer (CRC) is the third leading cause of cancer-related death in the United States, and screening has been shown to reduce mortality from CRC. Screening is underutilized in the United States, particularly in some communities such as Blacks/African Americans, American Indians/Alaskan Natives, and rural populations, contributing to disparities in mortality.
For CRC screening, mt-sDNA testing is one of several tests that are recommended by the United States Preventive Services Task Force (USPSTF). As part of a quality improvement program at our institution, those who are due for CRC screening are identified using a validated electronic algorithm and a kit is mailed directly to each patient. Our intervention is initiated on non-respondents to the mailed mt-sDNA outreach by testing the use of a technology-enabled reminder system.
Thirty days after being mailed a mt-sDNA kit, patients who have not completed the screening will be randomized to receive a reminder to complete the mt-sDNA screening by one of three mechanisms (time 0):
- Automated reminder using the EHR patient portal messaging system.
- Automated reminder using a customized interactive voice response (IVR) system
- Personalized reminder phone calls from the clinical team
This will allow for an empirical test of processes that can be employed to improve delivery of CRC screening and reduce preventable deaths in populations that are underserved with evidence-based interventions.
연구 유형
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- Mayo Clinic in Rochester
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adults, between 50 to 75 years old.
- Due for colorectal cancer screening based on not having a record of a colonoscopy within 10 years, sigmoidoscopy, or CT colonography within 5 years, mt-sDNA within 3 years, or FIT within 1 year.
- Asymptomatic for colorectal cancer such as rectal bleeding or reported abdominal mass.
Exclusion Criteria:
- For the intervention study, patients will be restricted to those aged 50 to 75 years and are due for colorectal cancer screening.
- We will exclude any patient who has:
- Had prior colonoscopy within 10 years, sigmoidoscopy within 5 years, mt-sDNA within 3 years, CT colonography within 5 years, and FOBT/FIT within twelve months of inclusion into the study;
- A diagnosis of CRC or other GI cancer;
- History of confirmed Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis) or other colitis;
- Had a colectomy, partial or total;
- A diagnosis of Lynch Syndrome;
- A diagnosis of Familial Adenomatous Polyposis (FAP);
- Iron deficiency anemia;
- Lower GI bleeding;
- A metastatic (Stage IV) blood or solid tumor cancer;
- End stage renal disease;
- A first degree relative with CRC prior to age 50 or 2+ first degree relatives diagnosed at any age.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: IVR Reminder
Participants will receive an interactive voice reminder
|
Participants will receive an interactive voice reminder (IVR) to complete mt-sDNA screening at day 7 and 21.
|
활성 비교기: Personalized Phone Call Reminder
Participants will receive a personalized phone call
|
Patients will receive a scripted phone call from the research team to remind them to complete the mt-sDNA screening at day 7 and 21.
|
활성 비교기: Portal Message Only
Participants will receive a online patient portal message reminder
|
Patients will receive an EHR patient portal message with a scripted message to remind them to complete the mt-sDNA screening at day 7 and 21.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Primary Endpoint (intention-to-treat)
기간: Completion by 6 months post randomization
|
The completion rate of mt-sDNA among eligible patients.
The primary comparison will be the return rate compared across intervention arms.
|
Completion by 6 months post randomization
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Secondary Outcome (per protocol analysis)
기간: Completion by 6 months post randomization
|
The completion rate of mt-sDNA among eligible patients.
The comparison will be the return rate compared across intervention arms, excluding participants who received an alternative intervention due to not having appropriate portal access.
|
Completion by 6 months post randomization
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Chyke Doubeni, MBBS, MPH, Mayo Clinic
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
IVR Reminder에 대한 임상 시험
-
Auritec PharmaceuticalsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); The University of Texas Medical Branch, Galveston 그리고 다른 협력자들완전한
-
Icahn School of Medicine at Mount Sinai완전한
-
National Institute of Allergy and Infectious Diseases...완전한
-
University of Alabama at BirminghamUS Department of Veterans Affairs; University of California, San Francisco; University of...완전한
-
National Institute of Allergy and Infectious Diseases...완전한
-
Johns Hopkins Bloomberg School of Public HealthInstitute of Epidemiology, Disease Control and Research완전한
-
Asante Health SystemHealth Resources and Services Administration (HRSA)완전한
-
M.D. Anderson Cancer CenterRobert Wood Johnson Foundation완전한
-
Harvard School of Public Health (HSPH)National Cancer Institute (NCI)완전한